证券日报网讯2月3日，力合科技（300800）在互动平台回答投资者提问时表示，公司持续关注工业过程 在线检测市场动态，在工业过程成分检测及自动化领域有一定技术储备，并已在相关场景落地应用。具 体经营情况请关注定期报告。 ...

根据灼识谘询的资料，尽管中国TIC服务市场高度分散，但中国却拥有超过53,000家TIC服务提供商。根 据灼识谘询的资料，按2024年的全球收入计，公司位列中国独立第三方TIC服务提供商第五。 据招股书，2023年-2024年，钛和检测实现收益分别为7.77亿元、8.02亿元；年内溢利分别为3720.1万 元、5002.99万元。 2025年前三季度，公司实现收益为5.91亿元，同比增长5.31%；期内溢利为1870.8万元，同比减少 15.55%。 瑞财经 吴文婷近日，钛和检测认证集团股份有限公司（以下简称"钛和检测"）在港交所递交招股书， 光大证券国际担任其独家保荐人。 钛和检测是检测、检验及认证解决方案服务提供商之一。透过提供符合合规及法规要求的TIC解决方案 服务，公司协助客户进行研发工作，并实现全球市场准入及营运可持续。公司的解决方案服务涵盖包括 通信、汽车、消费电子、食品、消费品、新能源产品、设施及建筑等多个领域。 资料显示，潘晶，女，53岁，为创始人、董事会主席兼执行董事以及总经理，主要负责集团总体战略规 划与发展。潘晶为控股股东之一。 潘晶在检测、检验及认证以及投资管理行业拥有逾22年经验。2 ...

（记者 王瀚黎） 每经AI快讯，有投资者在投资者互动平台提问：贵司检测中心涵盖安全、性能、可靠性、网络安全等 测试能力。请问网络安全领域是否已经形成营收？成功案例有哪些？ 天溯计量（301449.SZ）2月2日在投资者互动平台表示，公司的主营业务为计量校准、检测、认证等专 业技术服务，检测服务主要为消费类电池、动力电池及储能电池检测业务。目前，公司在网络安全领域 尚处于前期业务拓展中，该部分营收占公司总体收入比例较小。 ...

智通财经APP获悉，据港交所1月30日披露，钛和检测认证集团股份有限公司(以下简称：钛和检测)向港交所主板递交上市申请，光大证券国际为其独家保荐 人。 公司简介 | [编纂]的[编纂]數目:[编纂]股Ⅰ股(視乎[编纂]及[編纂]行使與否 | | --- | | 面定) | | 香港[编纂]數目 [编纂]股H股(可予重新分配) | | [编纂]數目 : [编纂]股H股(可予重新分配、視乎[编纂]及 | | [编纂]行使與否而定) | | [编纂] : 每股H股[編纂]港元加1.0%經紀佣金、 | | 0.0027% 證監會交易徵費、0.00565% 聯交所 | | 交易費及0.00015% 會財局交易徵費(須於 | | 申請時以港元繳足,多繳股款可予退還) | | 面值: 每股H股人民幣[编纂]元 | | 股份代號 : [·] | | 獨家保薦人、[编纂]、[編纂]、 | 钛和检测在国内外众多主要城市均设有广泛布局，涵盖中国内地、中国香港、美国、印尼及德国等10多个主要城市，并正于巴西筹建附属公司。 公司的服务帮助客户满足相关监管及行业标准，确保产品安全与功能性。此外，公司亦提供针对建筑及新能源行业的专业技术咨 ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Ti Testing & Certification Group Co., Ltd. 鈦和檢測認證集團股份有限公司 (A joint stock company incorporated in the People's Repub ...

根据北交所最新披露的信息，2026年1月29日，斯坦德检测集团股份有限公司IPO的状态从已受理变更 为已问询。 根据北交所最新披露的信息，2026年1月29日，斯坦德检测集团股份有限公司IPO的状态从已受理变更 为已问询。 ...

Core Viewpoint - The recent outbreak of Nipah virus in West Bengal, India, has led to significant market reactions, particularly in vaccine and diagnostic testing sectors, but the initial enthusiasm has waned as the actual impact on China appears minimal [2][5][26]. Group 1: Nipah Virus Overview - Nipah virus is not new; it was first identified in 1998 in Malaysia and has since been reported in several countries, including India and Bangladesh [7]. - The virus is primarily carried by fruit bats and can be transmitted to humans through contaminated food or direct contact with infected animals, with a high fatality rate exceeding 40% [7]. - The World Health Organization (WHO) classifies Nipah virus as a high-priority pathogen due to its severe health risks and lack of effective treatments or vaccines [7][8]. Group 2: Market Reactions - Following the outbreak news, A-share markets saw significant movements in vaccine and diagnostic testing stocks, with several companies experiencing price surges [3][4]. - However, as the Chinese health authorities confirmed no cases of Nipah virus within the country, the related stocks experienced substantial corrections [5][11]. Group 3: Industry Performance - The medical testing industry, which had thrived during the COVID-19 pandemic, is now facing significant performance pressures as demand for testing declines [15]. - Companies like Da An Gene, Saint Shine, and others that previously reported strong earnings are now forecasting losses for 2025, indicating ongoing financial strain [16][18]. - The vaccine sector is also under pressure, with many companies reporting losses and declining revenues due to intense competition and market saturation [19][20]. Group 4: Company-Specific Insights - Companies such as Cap Bio and Zhi Jiang Bio, which have developed Nipah virus testing products, have not reported significant new orders, suggesting limited market impact from the outbreak [18]. - The vaccine market is characterized by fierce competition, with companies like Zhifei Biological and Watson Bio facing challenges in maintaining profitability amid price wars and declining demand for core products [21][24]. - The overall sentiment in the market indicates that while the Nipah virus has raised awareness, it is unlikely to provide a sustainable boost to the financial performance of the medical testing and vaccine sectors [26].

Group 1 - The Nipah virus outbreak in West Bengal, India has led to confirmed cases and significant market reactions, particularly in vaccine and diagnostic sectors, with several stocks experiencing price surges [1][2] - The Nipah virus, first identified in 1998, has a high fatality rate exceeding 40% and lacks effective treatments, which raises public health concerns and market volatility [2][3] - Despite initial market enthusiasm, the lack of confirmed cases in China and the limited geographical impact of the outbreak have resulted in a significant stock price correction for related companies [1][4] Group 2 - Companies like Capbio, Zhijiang Bio, and others have developed Nipah virus testing products, but the overall demand for testing has not increased significantly due to the outbreak, leading to continued financial pressure on these firms [4][10] - The medical testing industry, previously buoyed by COVID-19 testing, is now facing declining revenues as demand decreases, with many companies reporting substantial losses [9][10] - The vaccine sector is also under pressure, with companies like Zhifei and Watson facing intense competition and declining sales, leading to significant financial challenges [15][20] Group 3 - The overall performance of companies in the vaccine and diagnostic sectors is expected to remain under pressure due to economic cycles, increased competition, and regulatory changes affecting pricing and profitability [12][20] - The Nipah virus outbreak has not translated into increased orders for testing products from domestic companies, indicating a lack of substantial market opportunity arising from the situation [12][22] - Investors are advised to be cautious, as the Nipah virus may not provide the expected boost to the performance of the medical testing and vaccine industries, which are already struggling with profitability [22]

市场监管总局今天（28日）公布2025"守护消费"铁拳行动第三批典型案例。 01 新疆维吾尔自治区巴音郭楞蒙古自治州轮台县市场监管局查处新疆蓝润能源有限公司破坏计量器具准确 度案 2024年5月21日，轮台县市场监管局依法对新疆蓝润能源有限公司进行计量监督检查时发现，当事人使 用的6台"贝林"牌燃油加油机，经现场检定均超过示值误差要求。经查，2022年7月1日至2024年5月21 日，当事人使用主板和计量芯片被改动，具有修改计量数据和税控数据功能的6台加油机对外销售成品 油，违法所得1009.09万元。 因当事人行为涉嫌犯罪，2024年7月18日，轮台县市场监管局依法将案件移送公安机关。后因公安机关 决定不予立案，轮台县市场监管局依法继续办理本案。 2025年11月25日，轮台县市场监管局依据《中华人民共和国计量法》《中华人民共和国计量法实施细 则》《加油站计量监督管理办法》有关规定，给予当事人没收涉案加油机6台、罚没款合计1009.19万元 的行政处罚。 市场监管部门主动提高技术手段和专业能力，不断破解复杂证据的固证难题，依法严厉打击计量作弊违 法行为，对不法经营者形成强力震慑，切实维护消费者的合法权益和市 ...

格隆汇1月27日丨天溯计量(301449.SZ)在投资者互动平台表示，公司的主营业务为计量校准、检测、认 证等专业技术服务，客户涉及生物医药、汽车、新能源、轨道交通、能源电力、轻工日化、装备制造等 国民经济多个领域。经核实，公司暂未和蓝箭航天有订单合作业务。 ...